Background and objective: Diebetes is frequently along with hyperlipidemia. Glycemic control could improve this condition and including statins and fibrates is the best option to aciliate this amelioration. Noting the importance of diabetes in terms of its multiple complications and the load of its huge cost on the sghoulders of the health system of our contry, this study aimed to to compare the efficacy of fenofibrate and gemfibrozil in improving lipid profile in patients with diabetes type II. Methods and materials: In this case-cotrol setting, a total of 60 diabetic patients with serum low-density lipoprotein (LDL) in the target range but with increased srum triglyceride were randomized in to 30-patient groups, receving either fenofibrate (200 mg/day) or gemfibrozil (450 mg/day) for 3 consecutive months. Lipid profile changes at the endpoint were compared between the two groups. Results: Although there were no significant differences between the two groups as to the percent changes in serum total cholesterol, triglyceride, high-density lipoprotein (HDL), Non-HDL, and LDL levels, the improvement was bettwe in fenofibrate receivers. No significant complications were documented in both groups. Conclusion: The efficacy of fenofibrate in improving serum lipid profile in diabetic patients is marginally better that that of gemfibrozil.